Glaukos (GKOS) Projected to Announce Quarterly Earnings on Wednesday

Glaukos (NYSE:GKOS) will likely be announcing its Q2 2026 results after the market closes on Wednesday, July 29th. Analysts expect Glaukos to post earnings of ($0.2235) per share and revenue of $150.9940 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 4:30 PM ET.

Glaukos (NYSE:GKOS) last posted its quarterly earnings results on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.12. The firm had revenue of $150.57 million for the quarter, compared to analysts’ expectations of $137.00 million. Glaukos had a negative net margin of 34.34% and a negative return on equity of 6.92%. The firm’s quarterly revenue was up 41.2% on a year-over-year basis. During the same period in the prior year, the company posted ($0.22) earnings per share. On average, analysts expect Glaukos to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Glaukos Price Performance

GKOS opened at $153.40 on Monday. The company has a 50-day moving average of $135.85 and a 200-day moving average of $123.52. The company has a market capitalization of $9.01 billion, a P/E ratio of -46.77 and a beta of 0.75. Glaukos has a 1-year low of $73.16 and a 1-year high of $161.53. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.73 and a current ratio of 5.43.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on GKOS. JPMorgan Chase & Co. lifted their price target on Glaukos from $120.00 to $140.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. Needham & Company LLC upped their price objective on Glaukos from $136.00 to $150.00 and gave the company a “buy” rating in a research note on Wednesday, June 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Glaukos in a report on Friday, July 17th. Truist Financial lifted their target price on Glaukos from $160.00 to $180.00 and gave the stock a “buy” rating in a research report on Thursday, July 16th. Finally, William Blair reiterated an “outperform” rating on shares of Glaukos in a report on Tuesday, May 26th. Thirteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $154.85.

Insider Buying and Selling

In related news, Director Gilbert H. Kliman sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $140.76, for a total value of $703,800.00. Following the sale, the director owned 35,528 shares of the company’s stock, valued at approximately $5,000,921.28. This trade represents a 12.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Leana Wen sold 1,700 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $143.35, for a total value of $243,695.00. Following the transaction, the director owned 19,739 shares of the company’s stock, valued at $2,829,585.65. This represents a 7.93% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 61,273 shares of company stock valued at $8,882,003 over the last quarter. Company insiders own 5.90% of the company’s stock.

Hedge Funds Weigh In On Glaukos

Several institutional investors have recently modified their holdings of GKOS. Smartleaf Asset Management LLC increased its holdings in shares of Glaukos by 9.7% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,383 shares of the medical instruments supplier’s stock worth $158,000 after acquiring an additional 122 shares during the period. Commonwealth Equity Services LLC boosted its stake in Glaukos by 1.7% during the 4th quarter. Commonwealth Equity Services LLC now owns 8,383 shares of the medical instruments supplier’s stock valued at $947,000 after purchasing an additional 144 shares during the period. Cetera Investment Advisers grew its position in Glaukos by 4.7% in the 4th quarter. Cetera Investment Advisers now owns 3,566 shares of the medical instruments supplier’s stock worth $403,000 after purchasing an additional 160 shares during the last quarter. Focus Partners Wealth grew its position in Glaukos by 6.9% in the 3rd quarter. Focus Partners Wealth now owns 2,714 shares of the medical instruments supplier’s stock worth $202,000 after purchasing an additional 176 shares during the last quarter. Finally, Maryland State Retirement & Pension System grew its position in Glaukos by 2.1% in the 4th quarter. Maryland State Retirement & Pension System now owns 8,422 shares of the medical instruments supplier’s stock worth $951,000 after purchasing an additional 177 shares during the last quarter. Institutional investors own 99.04% of the company’s stock.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.